Company news

Castle Biosciences, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

New Prospective, Multicenter Study Presented at SMR Demonstrates Castle Biosciences’ DecisionDx®-Melanoma Test Provides Significant Risk Prediction for Patients with Cutaneous Melanoma, Adding Value to Current Stage-Based Treatment Pathway Decisions

October 8, 2024

Castle Biosciences Hosts Groundbreaking Ceremony at Site of New Corporate Headquarters in Friendswood, Texas

October 1, 2024

New Data at ASTRO 2024 Shows Castle Biosciences’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma

September 26, 2024

New Data at AFS 2024 Demonstrates the Strength of Castle Biosciences’ TissueCypher® Test in Independently Predicting Risk of Developing Esophageal Cancer, Guiding Risk-Aligned Management Decisions for Patients with Barrett’s Esophagus

September 22, 2024

Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Named Arizona Bioscience Leader of the Year

September 15, 2024

DecisionDx®-Melanoma Can Identify Melanoma Patients with Low Risk of Sentinel Lymph Node Positivity Who May Safely Forego Biopsy Surgery, New Independent Study Affirms

September 10, 2024

Study Confirms the Ability of Castle Biosciences' DecisionDx®-SCC Test to Predict Likelihood of Benefit from Adjuvant Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma

September 4, 2024

Castle Biosciences Reports Second Quarter 2024 Results

August 4, 2024

Castle Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference

July 29, 2024

Castle Biosciences and Skin Cancer Survivor Teddi Mellencamp Arroyave Launch Campaign to Increase Awareness of Melanoma

July 21, 2024

Castle Biosciences to Release Second Quarter 2024 Financial Results and Host Conference Call on Monday, Aug. 5, 2024

July 14, 2024

Castle Biosciences Honored with Top Workplaces Awards

July 10, 2024

Recent AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences’ TissueCypher® Test

June 23, 2024

Castle Biosciences’ Founder, President and CEO Derek Maetzold Named an EY Entrepreneur Of The Year® 2024 Gulf South Award Winner

June 13, 2024

Castle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging Surveillance

May 29, 2024

New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis

May 28, 2024

Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference

May 14, 2024

Castle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett’s Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024

May 13, 2024

Castle Biosciences’ IDgenetix® Test Receives 2024 MedTech Breakthrough Award for “Best Overall Mental Health Solution”

May 9, 2024

Largest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class Result

May 7, 2024

DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck

May 2, 2024

Castle Biosciences Reports First Quarter 2024 Results

May 1, 2024

Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood’s Designation as a Sun Safe Leadership Model City by IMPACT Melanoma

April 29, 2024

Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024

April 10, 2024

Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year

April 9, 2024

Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations

April 9, 2024

Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer

April 3, 2024

Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

April 1, 2024

Castle Biosciences Announces Updates to its Board of Directors

March 26, 2024

Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year

March 24, 2024

Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB

March 21, 2024

Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy

March 18, 2024

New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older

March 14, 2024

Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum

March 11, 2024

Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting

March 7, 2024

In Novel Cohort, New Data Confirms DecisionDx®-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups

March 6, 2024

Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results

February 27, 2024

Study Finds DecisionDx®-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition Staging

February 25, 2024

Castle Biosciences to Release Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call on Wednesday, Feb. 28, 2024

February 6, 2024

New Study Highlights Significant Potential Medicare Savings Through Use of Castle Biosciences’ DecisionDx®-SCC Test to Guide Adjuvant Radiation Therapy Decisions in Patients with Cutaneous Squamous Cell Carcinoma

January 17, 2024

Castle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii®

January 13, 2024

Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Selected Among the Top 25 Women Leaders in Biotechnology by The Healthcare Technology Report

January 8, 2024

Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2023 Results

January 6, 2024

Study Finds Nurse Practitioners and Physician Assistants Would Alter Patient Care Decisions Based on DecisionDx®-Melanoma Test Results

November 30, 2023

Castle Biosciences Announces Multiple Data Presentations at the 2023 American Society for Dermatologic Surgery Annual Meeting

November 13, 2023

Castle Biosciences Ranked Among the Top Workplaces in Houston by the Houston Chronicle for the Third Consecutive Year

November 12, 2023

Real-World Evidence Confirms IDgenetix®-Guided Medication Management Significantly Improves Response and Remission Rates in Patients with Major Depressive Disorder

November 7, 2023

Castle Biosciences to Present at Upcoming Investor Conferences

November 7, 2023

Castle Announces Early Exploratory Study Data for Potential Development of a Complementary Test to Accompany DecisionDx®-UM That Could Aid in the Early Detection of Uveal Melanomas

November 2, 2023

Early Discovery Data Shows Ability of Castle Biosciences’ Pipeline Program to Distinguish Between Responders and Non-Responders to an Atopic Dermatitis Therapy

November 1, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 56 decks. Every deck is listed under its year.